The board of directors of CSPC Pharmaceutical Group Limited announced that dextromethorphan hydrobromide and quinidine sulphate orally disintegrating tablets (dextrometh Morphan hydrobromide 20 mg/quinidine sulphate 10 mg), a new Class 2.2 chemical drug developed by the Group, has obtained approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trial in China. The Product is a nervous system drug. The indication for this clinical trial approval is pseudobulbar affect (PBA), also known as pseudobulbar palsy.

The Product utilizes self-developed taste-blocking technology, which effectively overcomes the unique bitter and numbing taste of the active pharmaceutical ingredients. In comparison to the conventional capsules dosage form, it has the characteristic of administration without water. It is expected to solve the difficulties in swallowing medications for PBA patients with dysphagia.

Currently, there is no orally disintegrating tablets of this drug available in the global market.